← Back to Search

Control Arm for Coronavirus

Phase 2
Waitlist Available
Led By Franck Mauvais-Jarvias, MD, PhD
Research Sponsored by Tulane University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 60
Awards & highlights

Study Summary

This study is evaluating whether a short steroid therapy may help reduce the severity of symptoms and outcomes for individuals with confirmed COVID-19 positive patients.

Eligible Conditions
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 60
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 60 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Scores 1 or 2 on the 9-point World Health Organization (WHO) Ordinal Scale at Discharge, Measured up to Day 21
Secondary outcome measures
Grade 3 Adverse Events Occurrence
Length of Hospital Stay
Number of Days Death Occurred After Admission
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment2 Interventions
Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission and Progesterone 200mg by mouth daily for 5 days starting at admission.
Group II: Control ArmExperimental Treatment1 Intervention
Standard of Care along with placebo injection and placebo pill Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines

Find a Location

Who is running the clinical trial?

Tulane UniversityLead Sponsor
115 Previous Clinical Trials
226,492 Total Patients Enrolled
Franck Mauvais-Jarvias, MD, PhDPrincipal InvestigatorTulane University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
The LancetJournal
COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression
Mehta, Puja, Daniel F McAuley, Michael Brown, Emilie Sanchez, Rachel S Tattersall, and Jessica J Manson. 2020. “COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(20)30628-0.
The LancetJournal
Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China
Huang, Chaolin, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, Li Zhang, et al.. 2020. “Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(20)30183-5.
Statistics in MedicineJournal
Optimal Designs for Clinical Trials with Dichotomous Responses
Berry, Donald A., and Larry M. Pearson. 1985. “Optimal Designs for Clinical Trials with Dichotomous Responses”. Statistics in Medicine. Wiley. doi:10.1002/sim.4780040410.
Journal of Clinical InvestigationJournal
Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019
Chen, Guang, Di Wu, Wei Guo, Yong Cao, Da Huang, Hongwu Wang, Tao Wang, et al.. 2020. “Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019”. Journal of Clinical Investigation. American Society for Clinical Investigation. doi:10.1172/jci137244.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top